Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutrit...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2016-07-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Rivaroxaban-a-safe-therapeutic-option-in-patients-with-antiphospholipid-syndrome-Our-experience-in-23-cases,18,27997,1,1.html |
| _version_ | 1818247989256257536 |
|---|---|
| author | Ewa Haładyj Marzena Olesińska |
| author_facet | Ewa Haładyj Marzena Olesińska |
| author_sort | Ewa Haładyj |
| collection | DOAJ |
| description | In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutritional and therapeutic restrictions. The non-vitamin-K oral anticoagulants (NOAC) have a lot of advantages, but their efficacy and safety in APS have not been proven. We present 23 patients with APS treated with rivaroxaban in our department. Recurrence of thrombosis was observed only in 1 patient. No major or minor bleeding occurred. It proves the efficacy of treatment with rivaroxaban, but our observations require further prospective, randomized studies. |
| first_indexed | 2024-12-12T15:13:28Z |
| format | Article |
| id | doaj.art-af6cd885fa23452d9a5daaa102794c97 |
| institution | Directory Open Access Journal |
| issn | 0034-6233 2084-9834 |
| language | English |
| last_indexed | 2024-12-12T15:13:28Z |
| publishDate | 2016-07-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Rheumatology |
| spelling | doaj.art-af6cd885fa23452d9a5daaa102794c972022-12-22T00:20:34ZengTermedia Publishing HouseRheumatology0034-62332084-98342016-07-0154314614910.5114/reum.2016.6121727997Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 casesEwa HaładyjMarzena OlesińskaIn the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutritional and therapeutic restrictions. The non-vitamin-K oral anticoagulants (NOAC) have a lot of advantages, but their efficacy and safety in APS have not been proven. We present 23 patients with APS treated with rivaroxaban in our department. Recurrence of thrombosis was observed only in 1 patient. No major or minor bleeding occurred. It proves the efficacy of treatment with rivaroxaban, but our observations require further prospective, randomized studies.http://www.termedia.pl/Rivaroxaban-a-safe-therapeutic-option-in-patients-with-antiphospholipid-syndrome-Our-experience-in-23-cases,18,27997,1,1.htmlantiphospholipid syndrome rivaroxaban warfarin thrombosis |
| spellingShingle | Ewa Haładyj Marzena Olesińska Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases Rheumatology antiphospholipid syndrome rivaroxaban warfarin thrombosis |
| title | Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases |
| title_full | Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases |
| title_fullStr | Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases |
| title_full_unstemmed | Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases |
| title_short | Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases |
| title_sort | rivaroxaban a safe therapeutic option in patients with antiphospholipid syndrome our experience in 23 cases |
| topic | antiphospholipid syndrome rivaroxaban warfarin thrombosis |
| url | http://www.termedia.pl/Rivaroxaban-a-safe-therapeutic-option-in-patients-with-antiphospholipid-syndrome-Our-experience-in-23-cases,18,27997,1,1.html |
| work_keys_str_mv | AT ewahaładyj rivaroxabanasafetherapeuticoptioninpatientswithantiphospholipidsyndromeourexperiencein23cases AT marzenaolesinska rivaroxabanasafetherapeuticoptioninpatientswithantiphospholipidsyndromeourexperiencein23cases |